A Phase 1, Multicenter, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha (PDGFR alpha), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists.

Trial Profile

A Phase 1, Multicenter, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha (PDGFR alpha), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Tovetumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 25 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 25 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Planned end date changed from 1 Apr 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top